

The Impact of Metabolic Syndrome on A Cohort of Egyptian Rheumatoid Arthritis Patients

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Internal Medicine*

Presented by

Aly Moustafa Abd-el-samie

M.B., B.Ch

Under supervision of

Prof.Dr.Amina Badr Eldin Abdelaziz

Professor of Internal Medicine and Rheumatology

Faculty of Medicine- Ain-Shams University

Prof.Dr.Samah Abd El Rahman Elbakry

Professor of Internal Medicine and Rheumatology

Faculty of Medicine- Ain-Shams University

Dr. Caroline Samy Morad

Lecturer of Internal Medicine and Rheumatology

Faculty of Medicine- Ain-Shams University

*Faculty of Medicine
Ain Shams University*

2017

Acknowledgement

*First, I feel always indebted to **Allah**, the Most Kind and the Most Merciful.*

*I would like also to express my deep appreciation and gratitude to **Prof. Dr./ Amina Badr Eldin Abdelaziz**, Professor of Internal Medicine, Faculty of Medicine – Ain Shams University, for her unlimited help, great efforts and time she has devoted to accomplish this work, I really have the honor to complete this work under her supervision.*

*I am deeply grateful to **Prof. Dr./ Samah Abd El Rahman Elbakry**, Professor of Internal Medicine, Faculty of Medicine – Ain Shams University, for her unlimited help and giving me the privilege to work under her supervision. Her care and support are really valuable and precious.*

*I would like also to express my deep appreciation and gratitude to **Dr./Caroline Samy Morad**, Lecturer of Internal Medicine of Internal Medicine, Faculty of Medicine – Ain Shams University, for her care and support, also for the efforts and time she has devoted to accomplish this work,*

Finally, I wish to extend my thanks to my Family for their care and support.

 **Aly Moustafa**

﴿وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ

فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم
سورة النساء آية (١١٣)

List of Contents

Title	Page No.
List of Tables	5
List of Figures	9
List of Abbreviations	15
Introduction	1
Aim of the Work	20
Review of Literature	
▪ Rheumatoid Arthritis	21
▪ Metabolic Syndrome	65
▪ The Relation Between Metabolic Syndrome & Rheumatoid Arthritis	87
Patients and Methods	103
Results	110
Discussion	181
Summary	192
Conclusion	195
Recommendations	196
References	197
Arabic summary	

List of Tables

Table No.	Title	Page No.
Table (1):	The 2010 ACR/EULAR classification criteria for RA	41
Table (2):	Reference for biological DMARDs	62
Table (3):	Recommendations on Indications for the Use of Biologic Disease-Modifying Antirheumatic Drugs in Patients With RA	63
Table (4):	WHO, EGIR, and ATPIII definitions of the metabolic syndrome.....	65
Table (5):	IDF Metabolic Syndrome World-wide Definition	66
Table (6):	Ethnic Specific Values for Waist Circumference: International Diabetes Federation Consensus World Wide Definition of Metabolic Syndrome.....	71
Table (7):	Drugs with US Food and Drug Administration–Approved Indication for Obesity.....	83
Table (8-a):	Clinical descriptive data in group A.....	111
Table (8-b):	Clinical descriptive data in group A.....	95
Table (9):	Laboratory descriptive data in group A.....	113
Table (10):	Radiologically descriptive data in group A.....	114
Table (11):	Drug history in group A.....	115
Table (12-a):	Clinically descriptive data in group B.....	116
Table (12-b):	Clinically descriptive data in group B.....	100
Table (13):	Laboratory descriptive data in group B.....	118
Table (14):	Radiologically descriptive data in group B.....	119
Table (15):	Drug history in group B.....	120

List of Tables cont...

Table No.	Title	Page No.
Table (16):	Comparison between group A (patients RA with MetS) and group B (patients RA without MetS) regarding sex, age and duration of disease.....	121
Table (17):	Comparison between group A (patients with MetS) and group B (patients without MetS) regarding anthropometry.....	122
Table (18):	Comparison between group A (patients with MetS) and group B (patients without MetS) as regarding Diabetic, Hypertension, Family history.	125
Table (19):	Comparison between group A (patients with MetS) and group B (patients without MetS) as regarding DAS 28 Score & its components.....	127
Table (20):	Comparison between group A (patients without MetS) and group B (patients with MetS) as regarding blood chemistry.	128
Table (21):	Comparison between group A (patients without MetS) and group B (patients with MetS) as regarding radiological findings, HAQ Score, morning stiffness & limitation of movement.	131
Table (22-a):	Relation between DAS28 Score & clinical parameters in the two groups.....	134
Table (22-b):	Relation between DAS28 Score & clinical parameters in the two groups.....	118
Table (23):	Relation between DAS28 Score & laboratory parameters in the two groups.	136

List of Tables cont...

Table No.	Title	Page No.
Table (24):	Relation between DAS28 Score & radiological parameters in the two groups.	139
Table (25-a):	Relation between HAQ Score & clinical parameters in the two groups.	141
Table (25-b):	Relation between HAQ Score & clinical parameters in the two groups.	125
Table (26):	Relation between HAQ Score & laboratory parameters in the two groups.	147
Table (27):	Relation between HAQ Score & radiological parameters in the two groups.	155
Table (28):	Relation of bone erosions and deformity with each of sex, age and disease duration in group A (patients RA with MetS).	156
Table (29):	Relation of bone erosions and deformity with anthropometry in group A (patients RA with MetS).	158
Table (30):	Relation of bone erosions and deformity with diabetic, hypertension & family history in group A (patients RA with MetS).	160
Table (31):	Relation of bone erosions and deformity with DAS 28 Score & its components in group A (patients RA with MetS).	161
Table (32):	Relation of bone erosions and deformity with blood chemistry in group A (patients RA with MetS).	163

List of Tables cont...

Table No.	Title	Page No.
Table (33):	Relation of bone erosions and deformity with HAQ Sore, decrease joint space, morning stiffness & limitation movement in group A (patients RA with MetS).....	167
Table (34):	Relation of bone erosions and deformity with each sex, age & duration of disease in group B (patients RA without MetS)	169
Table (35):	Relation of bone erosions and deformity with anthropometry in group B (patients RA without MetS).....	171
Table (36):	Relation of bone erosions and deformity with each hypertension & family in group B (patients RA without MetS).....	172
Table (37):	Relation of bone erosions and deformity with DAS28 Score & its components in group B (patients RA without MetS).....	173
Table (38):	Relation of bone erosions and deformity with blood chemistry in group B (patients RA without MetS).....	175
Table (39):	Relation of bone erosions and deformity with each HAQ Score, dec. joint space, morning stiffness & limitation movement in group B (patients RA without MetS).	178
Table (40):	Comparison in group A of patients receiving statins as regard DAS and HAQ score.... Error! Bookmark not defined.	

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Signaling through PDGFRs promotes the proliferation and migration of FLSs, contributing to the formation of a pannus.....	27
Figure (2):	A healthy joint (left-hand side) contains a small volume of synovium and a thin lining layer of FLSs	29
Figure (3):	Synovial T cells may be activated by T-cell receptor (TCR) and co-stimulation pathways and by cytokine- or Toll-like receptor (TLR)-driven stimuli.....	31
Figure (4):	Boggy swelling in proximal interphalangeal and metacarpophalangeal joints (more prominent on patient's right hand) in a patient with new-onset rheumatoid arthritis.....	33
Figure (5):	Diagram demonstrating the 28 joints involved in DAS 28 score	44
Figure (6):	Effect of obesity on rheumatoid arthritis outcomes: disconnect between subjective disease activity and radiographic progression	89
Figure (7):	Obesity and cachexia and their association with markers of metabolic syndrome in RA.....	92
Figure (8):	Comparison between the two groups as regards weight (kg) and waist circumference (cm).	123
Figure (9):	Comparison between the two groups as regards Hip circumference and Height (cm).	123
Figure (10):	Comparison between the two groups as regards BMI.....	124

List of Figures cont...

Fig. No.	Title	Page No.
Figure (11):	Comparison between the two groups as regards Waist Hip Ratio.	124
Figure (12):	Comparison between the two groups as regards Diabetic.....	126
Figure (13):	Comparison between the two groups as regards Hypertension.....	126
Figure (14):	Comparison between the two groups as regards FBS.....	129
Figure (15):	Comparison between the two groups as regards 2 hrs PPBS.....	129
Figure (16):	Comparison between the two groups as regards cholesterol & triglycerides.....	130
Figure (17):	Comparison between the two groups as regards LDL & HDL.....	130
Figure (18):	Comparison between the two groups as HAQ score.	132
Figure (19):	Treatment used in patients of RA with MetS (group A) & treatment used in patients of RA without MetS (group B).....	133
Figure (20):	Correlation of DAS28 score with CRP in group A (patients of RA with MetS).....	137
Figure (21):	Correlation of DAS28 score with CRP in group B (patients of RA without MetS).....	138
Figure (22):	Correlation of DAS28 score with tender joint, swollen joints, decrease joint space & limitation movement in group A (patients of RA with MetS).....	140
Figure (23):	Correlation of DAS28 score with tender joint & limitation movement in group B (patients of RA without MetS).....	140
Figure (24):	Correlation of HAQ score with family history in group A (patients of RA with MetS).....	143

List of Figures cont...

Fig. No.	Title	Page No.
Figure (25):	Correlation of HAQ score with swollen joints in group A (patients of RA with MetS).....	144
Figure (26):	Correlation of HAQ score with morning stiffness in group A (patients of RA with MetS).....	144
Figure (27):	Correlation of HAQ score with limitation of movement in group A (patients of RA with MetS).....	145
Figure (28):	Correlation of HAQ score is with family history of RA in group B (patients of RA without MetS).....	145
Figure (29):	Correlation of HAQ score with limitation movement in group B (patients of RA without MetS).....	146
Figure (30):	Correlation of HAQ score with number of tender joints in group A (patients of RA with MetS).....	149
Figure (31):	Correlation of HAQ score with VAS in group A (patients of RA with MetS).....	149
Figure (32):	Correlation of HAQ score with number of swollen joints in group A (patients of RA with MetS).....	150
Figure (33):	Correlation of HAQ score with ESR in group A (patients of RA with MetS).....	150
Figure (34):	Correlation of HAQ score with serum albumin in group A (patients of RA with MetS).....	151
Figure (35):	Correlation of HAQ score with CRP in group A (patients of RA with MetS).....	151
Figure (36):	Correlation of HAQ score with Age in group B (patients of RA without MetS).....	152

List of Figures cont...

Fig. No.	Title	Page No.
Figure (37):	Correlation of HAQ score with duration of disease in group B (patients of RA without MetS).....	152
Figure (38):	Correlation of HAQ score with number of tender joints in group B (patients of RA without MetS).....	153
Figure (39):	Correlation of HAQ score with serum albumin in group B (patients of RA without MetS).....	153
Figure (40):	Correlation of HAQ score with serum urea in group B (patients of RA without MetS).....	154
Figure (41):	Correlation of HAQ score with CRP in group B (patients of RA without MetS).....	154
Figure (42):	Correlation of Deformity with duration of disease in group A (patients RA with MetS).....	157
Figure (43):	Correlation of Bone erosions with duration of disease in group A (patients RA with MetS).....	157
Figure (44):	Correlation of Deformity with weight in group A (patients RA with MetS).....	159
Figure (45):	Correlation of Deformity with waist circumference in group A (patients RA with MetS).....	159
Figure (46):	Correlation of deformity with hypertension in group A (patients RA with MetS).....	160
Figure (47):	Correlation of bone erosions with swollen joints in group A (patients RA with MetS).....	162

List of Figures cont...

Fig. No.	Title	Page No.
Figure (48):	Correlation of deformity with serum urea in group A (patients RA with MetS).....	164
Figure (49):	Correlation of bone erosions with serum urea in group A (patients RA with MetS).....	164
Figure (50):	Correlation of bone erosions with ESR in group A (patients RA with MetS).	165
Figure (51):	Correlation of deformity with FBS in group A (patients RA with MetS).	165
Figure (52):	Correlation of bone erosions with fasting blood sugar in group A (patients RA with MetS).....	166
Figure (53):	Correlation of bone erosions with 2 hours post prandial blood sugar in group A (patients RA with MetS).	166
Figure (54):	Correlation of deformity with decrease joint space in group A (patients RA with MetS).....	168
Figure (55):	Correlation of deformity with limitation movement in group A (patients RA with MetS).	168
Figure (56):	Correlation of bone erosions with decrease joint space in group A (patients RA with MetS).	169
Figure (57):	Correlation of bone erosions with age in group B (patients RA without MetS).	170
Figure (58):	Correlation of bone erosions with duration of disease in group B (patients RA without MetS).....	170

List of Figures cont...

Fig. No.	Title	Page No.
Figure (59):	Correlation of deformity with number of tender joints in group B (patients RA without MetS).....	174
Figure (60):	Correlation of bone erosions with number of swollen joints in group B (patients RA without MetS).....	174
Figure (61):	Correlation of bone erosions with 2 hours post prandial blood sugar in group B (patients RA without MetS).	177
Figure (62):	Correlation of deformity with triglycerides in group B (patients RA without MetS).....	177
Figure (63):	Correlation of deformity with decrease joint space in group B (patients RA without MetS).....	179
Figure (64):	Correlation of bone erosions with decrease joint space in group B (RA patients without MetS).	179
Figure (65):	Correlation of bone erosions with HAQ score in group B (RA patients without MetS).....	180

List of Abbreviations

Abb.	Full term
ACPA	<i>Anti-citrullinated peptide antibodies</i>
ACR.....	<i>American College of Rheumatology</i>
ACR/EULAR	<i>American College of Rheumatology and European League Against Rheumatism</i>
AF	<i>Abdominal fat</i>
ALLHAT	<i>Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial</i>
anti-CCP	<i>Anti-cyclic citrullinated peptides</i>
APF	<i>Antiperinuclear factor</i>
ATPIII.....	<i>Adult Treatment Panel III</i>
bDMARDs.....	<i>biological Disease modifying anti-rheumatic drugs</i>
BMD.....	<i>Bone mineral density</i>
BMI.....	<i>Body mass index</i>
CarP.....	<i>Carbamylated protein</i>
CCP.....	<i>Cyclic citrullinated polypeptide</i>
CD.....	<i>Crohn's disease</i>
CHD	<i>Coronary heart disease</i>
CNS	<i>Central nervous system</i>
COPD.....	<i>Chronic Obstructive Pulmonary Disease</i>
CRP.....	<i>C-reactive protein</i>
CSF1R.....	<i>Colony-stimulating factor 1 receptor</i>
CVD	<i>Cardiovascular disease</i>
CVR.....	<i>Cardiovascular risk</i>
DMARDs.....	<i>Disease modifying anti-rheumatic drugs</i>
EBV.....	<i>Epstein-Barr virus</i>
EGIR.....	<i>European Group for the Study of Insulin Resistance</i>
ESR.....	<i>Erythrocyte sedimentation rate</i>
FBS	<i>Fasting blood sugar</i>
FLS	<i>Fibroblast-like synoviocyte;</i>
FLSs.....	<i>Fibroblast-like synoviocytes</i>
FS.....	<i>Felty's syndrome</i>